CD274 and neoplasm: The immune checkpoint ligand CD274 (programmed death-ligand 1, B7-H1) inhibits anti-tumor immunity by interacting with the PDCD1 (programmed cell death 1, PD-1) receptor on T lymphocytes in various tumors (19, 20).